Media stories about Quidel (NASDAQ:QDEL) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Quidel earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.7660297414502 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

Quidel (QDEL) opened at $44.92 on Friday. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1,500.00, a price-to-earnings ratio of -280.75, a price-to-earnings-growth ratio of 1.47 and a beta of 1.02. Quidel has a 12-month low of $18.25 and a 12-month high of $49.47.

Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.21). The firm had revenue of $50.89 million for the quarter, compared to the consensus estimate of $50.47 million. Quidel had a negative return on equity of 2.36% and a negative net margin of 2.33%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. sell-side analysts forecast that Quidel will post -0.23 earnings per share for the current fiscal year.

QDEL has been the topic of a number of research analyst reports. Canaccord Genuity restated a “buy” rating and issued a $52.00 price target (up previously from $48.00) on shares of Quidel in a research note on Thursday, December 21st. BidaskClub upgraded Quidel from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Piper Jaffray Companies reiterated a “buy” rating and set a $50.00 price objective on shares of Quidel in a research report on Thursday, December 14th. Zacks Investment Research upgraded Quidel from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Friday, October 13th. Finally, CL King upgraded Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $53.50.

In other news, CEO Douglas C. Bryant sold 36,000 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $37.36, for a total transaction of $1,344,960.00. Following the sale, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at approximately $11,076,978.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Ratan S. Borkar sold 7,965 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $38.91, for a total value of $309,918.15. Following the sale, the senior vice president now directly owns 11,084 shares in the company, valued at $431,278.44. The disclosure for this sale can be found here. Insiders have sold a total of 385,790 shares of company stock worth $15,902,715 in the last quarter. Company insiders own 22.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Quidel (QDEL) Stock Price” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/02/04/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-quidel-qdel-stock-price.html.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.